Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
https://doi.org/10.17650/1994-4098-2019-15-3-37-43
Abstract
Background. Treatment of patients with advanced cancers of the female reproductive system is very challenging. The most common treatment scheme for such patients includes paclitaxel 135—175 mg/m2 + carboplatin AUC 5—6 or cisplatin 75 mg/m2. However, lengthy treatment with this regimen is limited by adverse events, such as neuropathy, allergic reactions, nephropathy, etc. The new micellar form of paclitaxel has demonstrated better tolerability compared to conventional paclitaxel and, considering the increased safe effective dose (up to 250 mg/m2) it should ensure higher efficacy and better progression-free survival. The use of cremophor EL free paclitaxel is recommended in patients with concomitant extragenital diseases (including diabetes and neurological deficit), in elderly patients, and in patients with allergic reactions, as well as in cases when additional steroids should be avoided.
Objective: to summarize the experience of using the new form of paclitaxel in patients with tumors of the female reproductive system and concomitant diseases.
Materials and methods. We analyzed both world and our own experience in using micellar paclitaxel at a dose of200—250 mg/m2 administered as a 1-hour intravenous infusion every 21 days for 3—6 treatment cycles in patients with solid tumors of the female reproductive system.
Results. The polymeric micellar composition of cremophor EL free paclitaxel can be used in higher therapeutic doses with a lower risk of hypersensitivity and peripheral neurotoxicity. Fatigue and neuropathy were the most common dose-dependent adverse events of this drug. Nonew adverse reactions unknown for paclitaxel have been registered.
Conclusions. The possibility of administration of micellar paclitaxel without premedication with steroids or at a minimum dose* makes it a promising candidate for further studies in combination with new targeted drugs and immunotherapy.
About the Authors
A. G. Kedrova
Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency of Russia
Russian Federation
Competing Interests: not
Russian Federation
28 Orekhovyy Boulevard, Moscow 115682
Competing Interests: not
S. E. Krasilnikov
Novosibirsk State Regional Clinical Oncologic Dispensary
Russian Federation
Competing Interests: not
Russian Federation
2 Plakhotniy St., Novosibirsk 630108
Competing Interests: not
D. A. Astakhov
Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency of Russia
Russian Federation
Competing Interests: not
Russian Federation
28 Orekhovyy Boulevard, Moscow 115682
Competing Interests: not
V. V. Kosyy
Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency of Russia
Russian Federation
Competing Interests: not
Russian Federation
28 Orekhovyy Boulevard, Moscow 115682
Competing Interests: not
References
1. Crown J., O’Leary M. The taxanes: an update. Lancet 2000;355:1176—8.
2. Mathew A.E., Mejillano M.R., Nath J.P. et al. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem 1992;35:145-51.
3. van Zuylen L., Karlsson M.O., Verweij J. et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001;47:309-18.
4. Di Maio M., Gallo C., Leighl N.B. et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015;33(8):910—5.
5. Vbn Euler H., Rivera P., Nyman H. et al. Phase I trial of Genexol-PM in ovarian cancer 10. A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. Vfet Comp Oncol 2013;11:243-55.
6. Hershman D.L., Lacchetti C., Dworkin R.H. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32(18):1941—67.
7. Saif M.W., Podoltsev N.A., Rubin M.S. et al. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 2010;28:186-94.
8. Vbn Hoff D.D., Ervin T., Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.
9. Zhao H., Li Q., Hong Z. et al. Paclitaxel-loaded mixed micelles enhance ovarian cancer therapy through extracellular pH-triggered PEG detachment and endosomal escape. J Mol Pharmaceutics 2016:13(7):2411—22. DOI: 10.1021/acs.molpharmaceut.6b00164.
10. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1-16.
11. Sutton D., Nasongkla N., Blanco E., Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24:1029-46.
12. Danson S., Ferry D., Alakhov V. et al. Phase I dose escalation and pharmacokinetic study of pluronic polymerbound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004;90:2085-91.
13. Kim T.Y., Kim D.W., Chung J.Y. et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16.
14. Kim S.C., Kim D.W, Shim Y.H. et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202.
15. Kim D.W., Kim S.Y., Kim H.K. et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-14.
16. Lee K.S., Chung H.C., Im SA et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108:241-50.
17. Park S.R., Oh D.Y., Kim D.W. et al. A multicenter, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 2004;12:1059-64.
18. Ostwal V., Sahu A., Zanwar S. et al. Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Indian J Med Res 2018;148:284-90.
19. Summary for US FDA, Inter-Agency Award 224-16-3001S. 24 July 2019. Available at: https://www.fda.gov/drugs/generic-drugs/generic-drugs-guidances-reports.
20. Quoc T.H., Jin M. Weekly regimen of PAXUS-PM, a novel cremophorfTee, with carboplatin in patients with advanced nonsmall-cell lung cancer in Vietnam. J Thor Oncol 2018;13(10S):P1.01-31, S471-2.
21. European Medicines Agency. Assessment report for Apealea. Available at: https://www.ema.europa.eu/documents/assessment-report/apealea-epar-public-assessment-report_en.pdf.
22. Lee S.W, KimY.M., Cho C.H. et al. An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). Cancer Res Treat 2018;50(1):195—203. DOI: 10.4143/crt.2016.376.
23. Чебеда А.Е., Белоусов Д.Ю. Сравнительный фармэкономический анализ препаратов Пакликал® и Таксол® в условиях Российской Федерации. Качественная клиническая практика. Фармакоэкономика 2016;(1):14—21. [Chebeda A.E., Belousov D.Yu. Comparative pharmacological analysis of Paclical® and Taxol® in the Russian Federation. Good clinical practice. Farmakoekonomika = Pharmacoeconomics 2016;(1):14—21. (In Russ.)].
Review
For citations:
Kedrova A.G., Krasilnikov S.E., Astakhov D.A., Kosyy V.V. Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system. Tumors of female reproductive system. 2019;15(3):37-43. (In Russ.) https://doi.org/10.17650/1994-4098-2019-15-3-37-43
Views:
720
Email this article 